Sanofi Discloses Total Voting Rights and Shares Information
Insight into Sanofi's Voting Rights and Shares
Sanofi, a prominent French société anonyme, is actively engaged in ensuring transparency regarding its corporate governance structures. As per the French Commercial Code and stock market regulations, the company provides regular updates on its total number of voting rights and shares. This article summarizes the latest information available.
Understanding the Regulations
The disclosure of total voting rights and shares is mandated by the French legislation under article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers. Such regulations are designed to promote transparency and protect the interests of shareholders.
Details as of June 2025
As of June 30, 2025, Sanofi reported a total of 1,227,756,274 issued shares. The number of real voting rights, excluding treasury shares, stood at 1,351,296,496. When including treasury shares, the theoretical number of voting rights reached 1,361,952,562.
Breaking Down the Figures
These figures are critical for investors as they determine the voting power within the company. Real voting rights reflect the shares currently held by investors, providing insight into actual influence over company decisions, while theoretical voting rights include all issued shares, thereby illustrating the total potential voting power.
Investor Relations Information
Sanofi places a strong emphasis on maintaining an open line of communication with its investors. The company encourages inquiries through its Investor Relations Department, which can be reached at investor.relations@sanofi.com.
Why This Information Matters
Understanding voting rights and share distributions is vital for shareholders who wish to understand their stake and influence in a company. Transparency in these matters enables investors to make informed decisions aligned with their investment strategies. Notably, updates like these reflect Sanofi's commitment to regulatory compliance and shareholder engagement.
Frequently Asked Questions
What is a total number of issued shares?
The total number of issued shares represents all shares that have been created and are currently in circulation among shareholders.
How are voting rights determined?
Voting rights are determined by the number of shares held by an investor, with each share typically representing one vote.
What is the difference between real and theoretical voting rights?
Real voting rights refer to shares currently held by investors, while theoretical voting rights include all issued shares, regardless of ownership status.
Why is transparency important for shareholders?
Transparency allows shareholders to understand their influence within a company and aids in making informed investment decisions.
How can shareholders contact Sanofi's Investor Relations?
Shareholders can contact Sanofi's Investor Relations by emailing investor.relations@sanofi.com.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
